Drug Profile
TP 252
Alternative Names: Eicosapentaenoic acid free fatty acid derivative - Thetis; EPA free fatty acid derivative - Thetis; EPA-FFA derivative - ThetisLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Thetis Pharmaceuticals
- Class Antineoplastics; Eicosanoids; Omega 3 fatty acids; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Familial adenomatous polyposis; Ulcerative colitis
Most Recent Events
- 09 Mar 2021 No development reported - Phase-II for Ulcerative colitis (Adjunctive treatment) in USA (PO)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Familial-adenomatous-polyposis in USA (PO)
- 23 May 2018 Thetis Pharmaceuticals receives SBIR grant from the National Institutes of Health for TP 252 development in Ulcerative colitis